Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Financing Activities (2022 - 2025)

Historic Cash from Financing Activities for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $8000.0.

  • Entrada Therapeutics' Cash from Financing Activities rose 17272.73% to $8000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 9794.92%. This contributed to the annual value of $103.0 million for FY2024, which is 38944.24% up from last year.
  • Entrada Therapeutics' Cash from Financing Activities amounted to $8000.0 in Q3 2025, which was up 17272.73% from $337000.0 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Cash from Financing Activities ranged from a high of $101.4 million in Q2 2024 and a low of -$11000.0 during Q3 2024
  • Moreover, its 4-year median value for Cash from Financing Activities was $350000.0 (2025), whereas its average is $8.3 million.
  • Per our database at Business Quant, Entrada Therapeutics' Cash from Financing Activities surged by 3897200.0% in 2023 and then crashed by 10298.91% in 2024.
  • Entrada Therapeutics' Cash from Financing Activities (Quarter) stood at $358000.0 in 2022, then surged by 92.74% to $690000.0 in 2023, then soared by 103.19% to $1.4 million in 2024, then plummeted by 99.43% to $8000.0 in 2025.
  • Its Cash from Financing Activities was $8000.0 in Q3 2025, compared to $337000.0 in Q2 2025 and $350000.0 in Q1 2025.